Would you offer adjuvant pembrolizumab to a stage II-III adenocarcinoma of the lung who had a complete pathologic response to 4 cycles of cisplatin/pemetrexed/pembro (KN-671)?  

The question posed is a central question of investigation and debate today.In my view, the patients most likely to derive benefit from adjuvant immunotherapy after receiving neo-adjuvant chemo-immunotherapy are those with the best responses to neo-adjuvant therapy. The patients I would least likely ...

We really can't draw any firm conclusions from the data available. Cross-trial comparisons are subjective to biases and inconsistencies between the populations included in the studies. That being said, the efficacy data suggests very similar event-free survival in CM-816 and KN-671, again, despite t...

For perioperative systemic therapy of NSCLC, current NCCN guidelines recommend neoadjuvant chemoimmunotherapy if patients are eligible for immune checkpoint inhibitors; the two listed options include either neoadjuvant nivolumab and platinum doublet chemotherapy every 3 weeks for 3 cycles followed b...